3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
24
Nivolumab
7
Early Intervention, Educational
7
Methods
6
durvalumab
5
aldesleukin
5
Trastuzumab
5
Paclitaxel
5
Fulvestrant
5
Carboplatin
5
atezolizumab
4
Surveys and Questionnaires
4
Patient Navigation
4
Docetaxel
4
Cyclophosphamide
4
Biopsy
4
fludarabine
3
Mass Screening
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Interleukin-2
3
Gene Expression Profiling
3
Fluorouracil
3
Educational Status
3
Bevacizumab
3
tremelimumab
2
spartalizumab
2
sargramostim
2
palbociclib
2
fludarabine phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
Breast
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled